News & Updates

Aficamten improves clinical outcomes in obstructive HCM
Aficamten improves clinical outcomes in obstructive HCM
30 Oct 2024 byStephen Padilla

Patients with obstructive hypertrophic cardiomyopathy (oHCM) can derive broad clinical benefits from treatment with aficamten, which include complete haemodynamic response and improved exercise capacity among others, as shown by the results of the SEQUOIA-HCM study.

Aficamten improves clinical outcomes in obstructive HCM
30 Oct 2024